ETBI set to become major player for diabetes management

Published: Thu, 02/05/15

 

Hello fellow investors / traders,
 
We found a new biotech play today that we think is ready to run - Eastgate Biotech (ETBI)
 
ETBI looks to have found strong support after pulling back over the past several weeks.
 
And priced at just $0.03 with a small market cap of around $2m, ETBI could be about to fly high.
 
What does ETBI do you ask?
 
ETBI is developing a way to deliver insulin by way of a tablet.
 
Both the nutraceutical and pharmaceutical industries are consistently looking out for innovative products that manage sugar in diabetes patience.

Glucora is the answer.

Glucora is a natural based formula in self-emulsifying delivery system that provides support for healthy glucose metabolism.

Used for the development of novel formulations and alternative dosage forms of existing biologically active molecules, Glucora receives an NPN (Natural Product Number 80057426 ) from the Natural and Non-Prescription Health Products Directorate of Health Canada for its natural product Glucora.

Data from the Centers for Disease Control and Prevention notes that 26 some million people currently have diabetes -- with about 90% to 95% of those cases being Type 2..

The world's population is aging fast, technology is improving, and public demand for more effective medications with fewer side effects is growing.

Global Industry Analysts projected the global market could be worth 10.1 billion dollars by 2017.

This is where ETBI comes in. Their R&D strategy and product analysis include the identification of biologically active compounds having limited absorption due to low solubility. 

EastGate Biotech's technology platform provides an effective delivery system with increased bioavailability of incorporated compounds.
 
The Company's approach increases solubility of hydrophobic compounds in a proprietary self-emulsifying vehicle using a safe combination of known and approved excipients. 
 
To date, Eastgate's sub-micron self-emulsifying delivery platform has been used for improvement of dietary supplements as well as pharmaceutical products. 

The Biotech sector is unique; however, Eastgate's technology extends beyond and places the Company into the Nutraceutical space.
 
Eastgate's products are patient friendly by design; they taste well and come in different forms and they are also designed to allow for the body to fully absorb the key pharmaceutical ingredients it needs. 

Eastgate recently signed a licensing agreement with New Jersey based Purine Pharma, LLC ('Purine') to produce and distribute Eastgate's line of nutraceuticals under its own private label.

Purine supplies a line of over 200 over-the-counter and prescription based cold, allergy, analgesic, topical and vitamin and supplement products, opening up Eastgate's opportunities to market and distribute their products in North America and internationally.

EastGate Biotech Provides Update On Its Patent Portfolio

SALT LAKE CITY and TORONTO, Feb. 3, 2015 /PRNewswire/ -- EastGate Biotech Corp. (ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules provides update on its patent portfolio for its sub-micron self-nanoemulsifying platform technology.

The company recently expanded its new pharmaceutical product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome.  In order to protect our innovation and know-how the company had filed these initial provisional patents:

US 61/947,678  Title:  Pharmaceutical Composition for Transmucosal Delivery

US 61/947,698  Title:  Treatment of Diabetes and Metabolic Syndrome

These two provisional patents relate specifically to the company's intraoral insulin formulation.  The company has outlined its sub-micron self-nanoemulsifying platform technology to develop alternative dosage forms for delivery of known biologically active molecules.  These technological approaches have demonstrated robustness and resulted in diversification of drug delivery products.  As a result, the company was able to develop an intraoral insulin tablet that is delivered to the mouth for intraoral insulin absorption (not GI-tract delivery).

The company will continue to prepare additional patent application filings in order to bolster the intellectual property and know-how of the intraoral insulin tablet and its other dosage forms.

The company already has patents for its intraoral Lorazepam Spray for acute seizures:

PCT/C2014/000126  Title:  Pharmaceutical Composition for Transmucosal Administration of Benzodiazepines

PCT/CA2014/000127  Title:  Pharmaceutical Composition For Enhanced Transmucosal Administration of Benzodiazepines

The company plans on expanding the patent portfolio for this indication as the clinical and scale-up manufacturing development continues.

"We are pleased with the expansiveness of our patent portfolio for our pharmaceutical products", says Anna Gluskin, CEO of EastGate Biotech Corp.  "The company's intent is to commercially-realize our unique sub-micron self-nanoemusifying delivery system and the breadth of the Intellectual Property  will open the doors to licensing partners interested in innovative drugs in the highly diverse marketplace", continues Gluskin.
 
 
In a nutshell...
 
With 50 million diagnosed - and 50 million undiagnosed - diabetes sufferers in North America alone gives an indication of the enormous market potential for ETBI's new insulin tablet.
 
Revolutionary treatment options, like the one Eastgate Biotech Corp are developing could become excellent in combination therapies that further enhance the effectiveness of existing medications and could, ultimately, give existing companies producing type 2 diabetes medications a chance to extend the revenue lifetime of their drug through combinations.
 
We think investor buzz in ETBI could continue to grow significantly in the coming weeks and months. Here is your chance to get in early before the masses. Make sure you continue your research and be ready.
 
www.ShiznitStocks.com
 

Disclaimer

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here.
ShiznitStocks.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein.  Instead ShiznitStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. ShiznitStocks.com does not offer such advice or analysis, and ShiznitStocks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, ShiznitStocks.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, ShiznitStocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. ShiznitStocks.com is not responsible for any claims made by the companies advertised herein. ShiznitStocks.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in ShiznitStocks.com statements and opinions and such statements and opinions cannot be considered independent. ShiznitStocks.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, ShiznitStocks.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. ShiznitStocks.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile. ShiznitStocks.com has been compensated two thousand dollars via electronic transfer from a non-affiliated third party for the profile of ETBI. ShiznitStocks.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated ShiznitStocks.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.  If ShiznitStocks.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.